Jen-Ai Hospital IPC

The Moderna COVID-19 vaccine is a messenger RNA (mRNA) based vaccine against coronavirus disease 2019 (COVID-19). The host cells receive the instruction from the mRNA to produce protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) and had negative baseline SARS-CoV-2 status, was approximately 94% based on a median follow-up of 9 weeks. The data reviewed at this time support the conclusion that the known and potential benefits of mRNA-1273 vaccine outweigh the known and potential risks

Very common (1/10) Headache, nausea, vomiting, myalgia, arthralgia and stiffness, pain at the injection site, fatigue, chills, fever, lymphadenopathy
Common (1/100 to ?1/10): Rash, injection site redness or swelling, vomiting, diarrhoea
Uncommon (1/1 000 to ?1/100): Itchiness at the injection site
Rare (1/10 000 to 1/1 000): Facial swelling, Bell’s palsy (acute peripheral facial paralysis)
Not known (cannot be estimated from available data): Anaphylaxis, hypersensitivity

The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vector vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) in clinical trials in the United Kingdom, Brazil and South Africa irrespective of interval between the doses, was 61%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. Additional data from the interim analyses of the trial in the United States show a vaccine efficacy of 76% against symptomatic SARS-CoV-2 infection. All data reviewed support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.

Very common (≥1/10): Tenderness, pain, warmth, itching or bruising at the injection site, fatigue, chills, headache, nausea, vomiting, myalgia, arthralgia
Common (≥1/100 to ˂1/10): Swelling or redness at the injection site, fever (≥38 °C)
Uncommon (≥1/1 000 to ˂1/100): Itchiness at the injection site
Very rare (? 1/10 000): Neuroinflammatory disorder (transverse myelitis) has been reported but a causal relationship with ChAdOx1-S/nCoV-19 [recombinant] has not been established.

Pfizer-BioNTech COVID-19 vaccine is a messenger RNA (mRNA) based vaccine against coronavirus disease 2019 (COVID-19). The mRNA instructs the cell to produce proteins of the S antigen (a piece of the spike protein unique to SARS-CoV-2) to stimulate an immune response. Efficacy shown in clinical trials in participants with or without evidence of prior infection with SARS-CoV-2 and who received the full series of vaccine (2 doses) was approximately 95% based on a median follow-up of two months.

Very common (≥1/10): Headache, arthralgia, myalgia, injection site pain, fatigue, chills, pyrexia (higher frequency after 2nd dose), injection site swelling
Common (≥1/100 to ˂1/10): Nausea, injection site redness
Uncommon (≥1/1 000 to ˂1/100): Lymphadenopathy, insomnia, pain in extremity, malaise, injection site itching
Rare (≥1/10 000 to ˂1/1 000): Bell’s palsy (acute peripheral facial paralysis)
Not known (cannot be estimated from available data): Anaphylaxis, hypersensitivity